Michigan is in the middle of a massive vaccination effort, but not everyone is getting on board.

For the study, U-M researchers used data from 154 critically ill Michigan Medicine patients from early March to late April to formulate their conclusions. At the end of 28 days after patients were put on a ventilator, 36% of patients of non-tocilizumab and 18% of tocilizumab patients died. For patients still at the hospital at the end of the study, 82% of tocilizumab patients and 53% of non-tocilizumab patients stopped using a ventilator. However, just over half of the tocilizumab patients developed an additional infection but only 26% of non-tocilizumab patients did. It was only given to 25% of tocilizumab patients and 20% of non-tocilizumab patients.

DETROIT A study from Henry Ford Health system is suggesting theres a benefit to hydroxychloroquine in treating the coronavirus (COVID-19). The study found 13% of people treated only with hydroxychloroquine died, compared to 26.4% who were not treated with hydroxychloroquine. What we think was important in our study, in our patients, is that patients were treated early, Dr. Marcus J. Zervos said. For hydroxychloroquine to have benefit, it has to be given before the patient suffers some of the severe immune reaction that can occur with COVID-19.Officials said 82% of the Henry Ford patients who received hydroxychloroquine received it within 24 hours of admission and 91% within 48 hours. Since the emergency use authorization has been rescinded by the FDA, researchers said hydroxychloroquine is not being used to treat patients in the Henry Ford Health System.

Leaders of a large study in the United Kingdom that is rigorously testing the malaria drug hydroxychloroquine and other medicines for hospitalized COVID-19 patients say they will stop putting people on the drug because its clear it isnt helping. Results released Friday from 1,542 patients showed the drug did not reduce deaths, time in the hospital or other factors. The results convincingly rule out any meaningful mortality benefit, study leaders at the University of Oxford said in a statement. The Oxford study is the largest study so far to put hydroxychloroquine to a strict test. The World Health Organization is leading a similar study testing hydroxychloroquine and several other therapies versus standard of care.

DETROIT – Study into hydroxychloroquine as a treatment for the coronavirus (COVID-19) has constantly evolved throughout the pandemic, and now, researchers are studying whether the drug can prevent the infection from developing in someone who was exposed to the virus. RECENTLY: New COVID-19 studies raise flags, under auditPreviously published studies have primarily focused on using hydroxychloroquine to treat COVID-19 after someone had already developed the infection, and to date, they have not been conclusive regarding benefit. A new study moved up the process and examined whether hydroxychloroquine can prevent an infection after someone is exposed. ResultsIn the end, there was no significant difference in the number of COVID-19 infections after exposure, and it was concluded that hydroxychloroquine was not found to have a benefit in preventing the development of COVID-19 after exposure. Henry Ford Hospital is still enrolling for the WHIP COVID-19 study of front line workers.

Can hydroxychloroquine prevent infection after exposure to coronavirus (COVID-19)? Published: June 4, 2020, 4:28 pmStudy into hydroxychloroquine as a treatment for the coronavirus (COVID-19) has constantly evolved throughout the pandemic, and now, researchers are studying whether the drug can prevent the infection from developing in someone who was exposed to the virus.

Last week, Local 4 discussed a very large study that raised concerns about hydroxychloroquine’s safety in COVID-19 patients. ORIGINAL STORY: Recent findings on hydroxychloroquine as coronavirus (COVID-19) treatment not favorableFrom the beginning of the pandemic, there has been a tidal wave of research into all things COVID-19. Because some of that research has turned out to be flawed, there has been more focus on research published in reputable journals. The New England Journal of Medicine’s paper under review suggested the use of blood pressure medications did not have any effect on death rates in COVID-19. Local 4 will keep viewers and readers updated with results of the reviews of the studies.

BANGKOK – The World Health Organization (WHO) said it will temporarily drop hydroxychloroquine — the malaria drug U.S. President Trump said he is taking — from its global study into experimental COVID-19 treatments. WHO director-general Tedros Adhanom Ghebreyesus said there would be a “temporary pause" on the hydroxychloroquine arm of its global clinical trial. The announcement came after a paper in the Lancet showed that people taking the drug were at higher risk of death and heart problems. Still, several countries in Europe and North Africa are using chloroquine and hydroxychloroquine to treat COVID-19 patients. Other treatments in the WHO study, including the experimental drug remdesivir and an HIV combination therapy, are still being pursued.

Andrew Cuomo, who has presided over the state with the highest death toll from the scourge, rang the bell to set off trading at the NYSE. But in the years since, the rise of electronic trading from computer terminals grew to dominate the action on Wall Street. The true death toll is widely believed to be significantly higher, with experts saying many victims died of the virus without ever being tested for it. Trump several months ago likened the coronavirus to the flu and dismissed worries it could lead to so many deaths. Russia reported a record one-day spike Tuesday of 174 deaths, bringing the country’s confirmed death toll to over 3,800.

DETROIT – There are two drugs at the center of the battle against the coronavirus (COVID-19): hydroxychloroquine and remdesivir. Here’s what we know about the research into both. Remdesivir shipmentThere’s also an update on the distribution of remdesivir to patients in the state of Michigan. On Saturday, state officials received 1,600 vials of the drug from the United States supply, enough for about 145 critically ill patients. The state is prioritizing distribution to communities with the highest death rates and most patients with COVID-19 on ventilators.

What we know about 2 drugs at center of coronavirus (COVID-19) vaccine researchPublished: May 14, 2020, 4:09 pmThere are two drugs at the center of the battle against the coronavirus (COVID-19): hydroxychloroquine and remdesivir. Here’s what we know about the research into both.

The Henry Ford Health System is calling for participation in the “Will Hydroxychloroquine Impede or Prevent COVID-19” study. The study, now being referred to as “WHIP COVID-19," is a 3,000-subject look at whether hydroxychloroquine prevents front-line workers from contracting the COVID-19 virus. Henry Ford Health is now enrolling:“Participation in this study is completely voluntary. Then, an informed consent process will take place with those who potentially meet parameters of the study. During the consent process, volunteers will have an opportunity to have any questions about participation addressed, prior to enrollment in the study.

DETROIT – State Rep. Karen Whitsett (D-Detroit) found out she had tested positive for coronavirus (COVID-19) the day her friend and House colleague died from it. Her health was deteriorating fast and she prevailed upon her doctor to get hydroxychloroquine for her. “I thank God the president of the United States mentioned that drug because it did save me,” Whitsett said. “Congratulations to State Representative Karen Whitsett of Michigan. She has the utmost respect for how Detroit Mayor Mike Duggan is handling the crisis.

Michigan Rep. Karen Whitsett credits hydroxychloroquine, President Trump for her recovery from COVID-19Published: April 6, 2020, 11:10 pmState Rep. Karen Whitsett (D-Detroit) found out she had tested positive for coronavirus (COVID-19) the day her friend and House colleague died from it.

Doctors are using it in certain coronavirus (COVID-19) cases, but they’re emphasizing that it has to be used responsibly and cleared by medical experts. UPDATE -- MARCH 30, 2020: Michigan coronavirus cases up to 6,498; Death toll now at 184Michigan Gov. Doctors and hospitals treating patients with severe COVID-19 aren’t dismissing the possibility that hydroxychloroquine might be beneficial, and most are using it on COVID-19 positive patients, especially the more severe cases. Doctors said that’s because the potential benefit, which remains completely unknown right now, outweighs the harm in severe cases. Sandoz, the manufacturer of Plaquenil, has donated 30 million doses of the drug to the Strategic National Stockpile as a possible treatment for COVID-19 patients.